Abaloparatide
Also known as: Tymlos
Abaloparatide is a PTHrP(1-34) analog that agonizes the PTH1 receptor with preference for its transient RG conformation, activating cAMP signaling to stimulate osteoblast-driven new bone formation.
- Drug class
- Anabolic osteoporosis agent (PTHrP analog)
- Primary targets
- PTH1 receptor (PTH1R)
- Dose reference
- FDA label reference dose: 80 mcg subcutaneously once daily (a labeled dose, not a recommendation)
- Half-life
- Approximately 1-1.7 hours (FDA label)
- Developer / origin
- Invented at Ipsen (BA058); developed and marketed by Radius Health as Tymlos
- Reference year
- 2017
- Evidence score
- 4/5 - Strong approval-grade clinical evidence
Approved uses
- Treatment of postmenopausal women with osteoporosis at high risk for fracture
- Treatment of men with osteoporosis at high risk for fracture
Strong approval-grade clinical evidence
Abaloparatide is FDA-approved with phase 3 randomized trial support: ACTIVE showed reduced vertebral and nonvertebral fractures versus placebo in postmenopausal women, ACTIVExtend supported sequential maintenance benefit, and ATOM supported the male bone-density indication. Evidence is robust for women's fracture endpoints and solid but density-based for men.
Investigational compound with human randomized or phase 2/3 evidence.
Evidence basis
- ACTIVE phase 3 RCT (JAMA 2016, n=2463) showed significant vertebral and nonvertebral fracture reduction vs placebo
- ACTIVExtend demonstrated continued benefit with sequential alendronate
- ATOM phase 3 RCT (n=228) supported the 2022 male indication via bone mineral density
- FDA approvals 2017 (women) and 2022 (men) with DailyMed labeling
- Male approval rests on BMD rather than a fracture-endpoint trial, a noted limit
How to read this entry
Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.
Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.
Abaloparatide guides
Read the matching guide or adjacent research pages for more context.
Peptide calculators
Use calculators for concentration, unit conversion and repeated-dose accumulation math.
Compare with related peptides
Stay inside the same research category and compare mechanism, status and evidence quality.
Larazotide
Larazotide acetate, AT-1001
An oral, gut-restricted peptide that antagonizes zonulin signaling to limit gluten-driven intestinal tight-junction permeability in celiac disease.
Lanreotide
Somatuline Depot, Somatuline Autogel
Lanreotide binds with high affinity to somatostatin receptors 2 and 5, mimicking native somatostatin to suppress growth hormone, IGF-1 and various neuroendocrine and gut hormones.
Teriparatide
Forteo, Bonsity, PTH 1-34
Once-daily injection produces intermittent activation of the PTH1 receptor on osteoblasts, preferentially stimulating bone formation over resorption to increase bone mass.
Calcitonin
Miacalcin, Fortical, salmon calcitonin
Calcitonin activates the calcitonin receptor on osteoclasts to inhibit bone resorption and lower blood calcium, with additional actions on the kidney and gastrointestinal tract.